CSIMarket Company Name, Ticker, Customers, else..
 
Anaptysbio Inc   (NASDAQ: ANAB)
 
Price: $55.2800 $-1.75 -3.069%
Day's High: $58.09000015258789 Week Perf: -4.69 %
Day's Low: $ 54.84 30 Day Perf: 3.02 %
Volume (M): 773,855 52 Wk High: $ 72.36
Volume (M$): $ 0 52 Wk Avg: $40.58
Open: $56.82 52 Wk Low: $11.40



 Market Capitalization (Millions $) 1,586
 Shares Outstanding (Millions) 29
 Employees 104
 Revenues (TTM) (Millions $) 232
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) 150
 Capital Exp. (TTM) (Millions $) 0

Business Description


AnaptysBio Inc. is a biotechnology company that focuses on the discovery and development of antibody therapeutics. The company harnesses the power of its proprietary somatic hypermutation (SHM) platform to generate novel antibodies for various diseases across different therapeutic areas. Through its platform, AnaptysBio can create fully human antibodies with improved binding affinity, specificity, and potency, thereby potentially providing more effective treatments for patients. The company collaborates with pharmaceutical partners to advance its pipeline of antibody candidates, aiming to address unmet medical needs and make a positive impact in the field of biopharmaceuticals.


   Company Address: 10770 Wateridge Circle San Diego 92121 CA
   Company Phone Number: 362-6295   Stock Exchange / Ticker: NASDAQ ANAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.18%    
BMY   -1.47%    
JNJ   -0.71%    
LLY   -5.97%    
MRK   -4.21%    
PFE   -0.07%    
• View Complete Report
   



Clinical Study

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-S...

Published Mon, Nov 10 2025 2:45 PM UTC

AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results from its Phase 2 trial for rosnilimab in the treatment of moder...
Clinical Study

AnaptysBio Unveils Promising Clinical Trial Results for Novel Immunology Therapeutics

Published Wed, Oct 29 2025 1:45 PM UTC

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics, has recently disclosed promising clinical trial outcomes for two of its lead investigational drugs. The announcement was made during the American College of Rheumatology (ACR) Convergence 2025 in Chicago and includes significant progress in the ...
Management Announcement

Anaptys Biosciences Announces Successful Completion of $100 Million Underwritten Registered Direct Offering, Fueling Growth Momentum

Published Wed, Aug 14 2024 9:00 AM UTC



San Diego-based clinical-stage biotechnology company, Anaptys Biosciences, has recently announced the successful completion of a $100 million underwritten registered direct offering. This landmark transaction was led by long-standing investor EcoR1 Capital, with notable participation from additional existing and new investors, including pharmaceutical giant Sanofi....
Clinical Study

AnaptysBio's Imsidolimab Shows Positive Results in Treating Generalized Pustular Psoriasis

Published Thu, May 9 2024 8:10 PM UTC

AnaptysBio, a clinical-stage biotechnology company, has recently reported positive top-line results from their Phase 3 clinical trials involving the experimental drug imsidolimab (IL-36R mAb). Designed to address the challenges posed by generalized pustular psoriasis (GPP), a severe orphan disease known for its potential life-threatening consequences, these trials evaluated ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.82
Price to Sales (Expected) -
Price to Book 124.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.24
Working Capital Ratio 7.99
Leverage Ratio (MRQ) 3.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.24 $
Revenues (TTM) 8.1 $
Cash Flow (TTM) 5.22 $
Cash 9.98 $
Book Value 0.44 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,234,500
Net Income per Employee (TTM) -257,567
Receivable Turnover Ratio (TTM) 5.93
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.68

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -135.53 %
Net Margin (MRQ) -206.93 %
Net Cash Flow Margin (MRQ) 40.2 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Anaptysbio Inc's Segments
Royalty Management    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.